Feb 19, 2026 08:30AM
Feb 12, 2026 08:00AM
Dec 21, 2025 04:00AM
Dec 17, 2025 08:02AM
Dec 17, 2025 08:00AM
Nov 8, 2025 04:57PM
Nov 8, 2025 04:57PM New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
Oct 30, 2025 08:00AM
Oct 10, 2025 06:40AM
Oct 1, 2025 07:30AM
Oct 1, 2025 07:30AM
Sep 29, 2025 06:58PM
Sep 28, 2025 11:13AM
Sep 28, 2025 11:13AM New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
Sep 28, 2025 11:13AM
Aug 30, 2025 04:00PM
Aug 30, 2025 10:30AM
Aug 30, 2025 10:30AM
Aug 30, 2025 10:30AM
Aug 30, 2025 10:30AM
Aug 30, 2025 10:30AM Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
Aug 30, 2025 10:30AM
Aug 30, 2025 10:30AM
Aug 11, 2025 08:00AM
Jul 31, 2025 08:00AM
Jun 9, 2025 06:00AM
Jun 9, 2025 06:00AM
May 17, 2025 05:50AM AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
May 1, 2025 08:00AM
Apr 28, 2025 08:00AM
Apr 28, 2025 08:00AM
Apr 12, 2025 04:00AM
Apr 11, 2025 09:44AM
Apr 10, 2025 05:32AM
Mar 31, 2025 05:21AM Alnylam Pharmaceuticals (ALNY) PT Raised to $345 at Stifel
Mar 29, 2025 01:00PM
Mar 28, 2025 04:45PM
Mar 28, 2025 04:44PM
Mar 24, 2025 08:58AM
Mar 24, 2025 06:43AM
Mar 21, 2025 07:44AM
Mar 21, 2025 06:56AM Alnylam Pharmaceuticals (ALNY) PT Raised to $338 at Scotiabank
Mar 21, 2025 06:46AM
Mar 20, 2025 05:57PM
Mar 20, 2025 05:54PM
Feb 26, 2025 08:10AM
Feb 25, 2025 07:00AM
Feb 25, 2025 06:45AM
Feb 13, 2025 08:00AM Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress
Jan 14, 2025 06:44AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All